Results announcement for the second quarter 2013

GSK Press Release:

Results announcement for the second quarter 2013

Wednesday 24 July 2013, London UK

GSK announces Q2 core EPS growth of 4% and dividend of 18p

• Core EPS growth of 4% on sales growth of 2% (both CER)
• Pharma & Vaccines +1%; US +5%; EMAP +2%; Europe flat; Japan -5%
• Consumer Healthcare +2% (+5% excluding divestments)
• 3 major US approvals: Breo Ellipta for COPD, Tafinlar & Mekinist for metastatic melanoma
• Q2 dividend of 18p (+6%)
• Total share repurchases for 2013 to be £1-2bn

View full Q2 2013 results (PDF)

More details with CFO interview available in the quarterly results section of this website.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.